ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck’s Ebola vaccine arrives in Congo

by Lisa M. Jarvis
May 21, 2018 | APPEARED IN VOLUME 96, ISSUE 21

 

A first batch of Merck & Co.’s experimental Ebola vaccine, V920, has arrived in Kinshasa, Democratic Republic of the Congo, according to the World Health Organization. The 4,000 doses of vaccine are meant to stem the spread of the deadly virus following a fresh outbreak in the region. As of May 14, 44 cases, including at least 23 deaths, have been reported in Congo. Merck licensed V920 from NewLink Genetics in 2014 amid an eruption of Ebola virus in West Africa that claimed more than 11,000 lives.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment